Emerging drug profile: cyclin-dependent kinase inhibitors

References

• Hirama T, Koeffler H. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995;86:841–854.
   PubMed Web of Science ®Google Scholar
• Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004; 116:221–234.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57–70.
   PubMed Web of Science ®Google Scholar
• Jeffrey PD, Russo AA, Polyak K, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995; 376:313–320.
   PubMed Web of Science ®Google Scholar
• Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973–2978.
   PubMed Web of Science ®Google Scholar
• Leoncini L, Bellan C, De Falco G. Retinoblastoma gene family expression in lymphoid tissues. Oncogene 2006;25:5309–5314.
   PubMed Web of Science ®Google Scholar
• Morgan DO. Principles of CDK regulation. Nature 1995;374:131–134.
   PubMed Web of Science ®Google Scholar
• van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993;262:2050–2054.
   PubMed Web of Science ®Google Scholar
• Hu B, Mitra J, van den Heuvel S, et al. S and G2 phase roles for CDK2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 2001;21:2755–2766.
   PubMed Web of Science ®Google Scholar
• Cai D, Latham VM Jr, Zhang X, et al. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006;66:9270–9280.
   PubMed Web of Science ®Google Scholar
• Wei F-Y, Tomizawa K. Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus. Mini Rev Med Chem 2007;7: 1070–1074.
   PubMed Web of Science ®Google Scholar
• Bregman DB, Pestell RG, Kidd VJ. Cell cycle regulation and RNA polymerase II. Front Biosci 2000;5:D244–D257.
   PubMed Web of Science ®Google Scholar
• Oelgeschläger T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002;190: 160–169.
   PubMed Web of Science ®Google Scholar
• Sims RJ, Belotserkovskaya R, Reinberg D. Elongation by RNA polymerase II: the short and long of it. Genes Dev 2004;18:2437–2468.
   PubMed Web of Science ®Google Scholar
• Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91:3379–3389.
   PubMed Web of Science ®Google Scholar
• Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998;25:11–18.
   PubMed Web of Science ®Google Scholar
• Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood 2002;100:194–199.
   PubMed Web of Science ®Google Scholar
• Pepper C, Thomas A, Hoy T, et al. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;107:611–615.
   PubMed Web of Science ®Google Scholar
• Chawla-Sarkar M, Bae SI, Reu FJ, et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004;11:915–923.
   PubMed Web of Science ®Google Scholar
• Manohar SM, Rathos MJ, Sonawane V, et al. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res 2011;35:821–830.
   PubMed Web of Science ®Google Scholar
• Mohanakumara P, Sreejayan N, Priti V, et al. Dysoxylum binectariferum Hook.f (Meliaceae), a rich source of rohitukine. Fitoterapia 2010;81:145–148.
   PubMed Web of Science ®Google Scholar
• Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86–8275. J Natl Cancer Inst 1992;84:1736–1740.
   PubMed Web of Science ®Google Scholar
• Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996;56:4856–4861.
   PubMed Web of Science ®Google Scholar
• Brüsselbach S, Nettelbeck DM, Sedlacek HH, et al. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 1998;77:146–152.
   PubMed Web of Science ®Google Scholar
• Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92:376–387.
   PubMed Web of Science ®Google Scholar
• Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276:31793–31799.
   PubMed Web of Science ®Google Scholar
• de Azevedo WF Jr, Canduri F, da Silveira NJF. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002;293:566–571.
   PubMed Web of Science ®Google Scholar
• Baumli S, Lolli G, Lowe ED, et al. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J 2008;27:1907–1918.
   PubMed Web of Science ®Google Scholar
• König A, Schwartz GK, Mohammad RM, et al. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997;90:4307–4312.
   PubMed Web of Science ®Google Scholar
• Parker BW, Kaur G, Nieves-Neira W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458–465.
   PubMed Web of Science ®Google Scholar
• Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood 1998;91:2482–2490.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92:3804–3816.
   PubMed Web of Science ®Google Scholar
• Christian BA, Grever MR, Byrd JC, et al. Flavopiridol in chronic lymphocytic leukemia: a concise review. Clin Lymphoma Myeloma 2009;9(Suppl. 3):S179–S185.
   PubMedGoogle Scholar
• Shapiro GI, Koestner DA, Matranga CB, et al. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1999;5:2925–2938.
   PubMed Web of Science ®Google Scholar
• Kitada S, Zapata JM, Andreeff M, et al. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96: 393–397.
   PubMed Web of Science ®Google Scholar
• Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009;113:2637–2645.
   PubMed Web of Science ®Google Scholar
• Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup phase III trial E2997. J Clin Oncol 2007;25:799–804.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Chen R, Keating MJ, Gandhi V, et al. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005;106:2513–2519.
   PubMed Web of Science ®Google Scholar
• Hussain S-RA, Lucas DM, Johnson AJ, et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 2008;111:3190–3199.
   PubMed Web of Science ®Google Scholar
• Mahoney E, Lucas DM, Gupta SV, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood 2012;120: 1262–1273.
   PubMed Web of Science ®Google Scholar
• Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16:2986–2999.
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001;7:1590–1599.
   PubMed Web of Science ®Google Scholar
• Stadler WM, Vogelzang NJ, Amato R, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000;18:371–375.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, O’Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20: 2157–2170.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001;19:1985–1992.
   PubMed Web of Science ®Google Scholar
• Lin TS, Howard OM, Neuberg DS, et al. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 2002;43:793–797.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Byrd JC, Bartlett N, et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005;29:1253–1257.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005;11:4176–4181.
   PubMed Web of Science ®Google Scholar
• Shinn C, Larsen D, Suarez J-R. Flavopiridol sensitivity of chronic lymphocytic leukemia (CLL) cells in vitro varies based upon species specific drug protein binding. Blood 2000;96:294b. [Abstract]
   Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399–404.
   PubMed Web of Science ®Google Scholar
• Messmann RA, Ullmann CD, Lahusen T, et al. Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clin Cancer Res 2003;9:562–570.
   PubMed Web of Science ®Google Scholar
• Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27: 6012–6018.
   PubMed Web of Science ®Google Scholar
• Stephens DM, Ruppert AS, Blum K, et al. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica 2012;97:423–427.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382–3391.
   PubMed Web of Science ®Google Scholar
• Lanasa MC, Andritsos L, Brown JR, et al. Interim analysis of EFC6663, a multicenter phase 2 study of alvocidib (flavopiridol), demonstrates clinical responses among patients with fludarabine refractory CLL. Blood 2010;116(Suppl. 1): Abstract 58.
   Google Scholar
• Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010;28:418–423.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012;120: 3986–3996.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee B-N, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
   PubMed Web of Science ®Google Scholar
• Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 2003;22:7108–7122.
   PubMed Web of Science ®Google Scholar
• Dai Y, Rahmani M, Pei X-Y, et la. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 2004;104:509–518.
   PubMed Web of Science ®Google Scholar
• Holkova B, Perkins EB, Ramakrishnan V, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 2011;17:3388–3397.
   PubMed Web of Science ®Google Scholar
• Paruch K, Dwyer MP, Alvarez C, et al. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med Chem Lett 2010;1:204–208.
   PubMed Web of Science ®Google Scholar
• Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010;9:2344–2353.
   PubMed Web of Science ®Google Scholar
• Johnson AJ, Yeh Y-Y, Smith LL, et al. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 2012;26:2554–2557.
   PubMed Web of Science ®Google Scholar
• Baiocchi RA, Flynn JM, Jones JA, et al. Early evidence of anti-lymphoma activity of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in heavily pre-treated low grade lymphoma and diffuse large cell lymphoma patients. Blood 2010;116(Suppl. 1): Abstract 3966.
   Google Scholar
• Flynn JM, Jones JA, Andritsos L, et al. Update on the phase I study of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): confirmation of clinical activity and feasibility of long-term administration. Blood 2010;116(Suppl. 1): Abstract 1396.
   PubMed Web of Science ®Google Scholar
• Mita MM, Mita AC, Mosely J, et al. A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. J Clin Oncol 2011;29(Suppl.): Abstract 3080.
   Google Scholar
• Flynn JM, Jones JA, Andritsos L, et al. Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. J Clin Oncol 2011;29(Suppl.): Abstract 6623.
   Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Siemeister G, Lücking U, Wengner AM, et al. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol Cancer Ther 2012;11:2265–2273.
   PubMed Web of Science ®Google Scholar
• Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 2007;6:918–925.
   PubMed Web of Science ®Google Scholar
• Joshi KS, Rathos MJ, Mahajan P, et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther 2007;6:926–934.
   PubMed Web of Science ®Google Scholar
• Raje N, Hideshima T, Mukherjee S, et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009;23:961–970.
   PubMed Web of Science ®Google Scholar
• Hirte HW, Raghunadharao D, Baetz T, et al. A phase 1 study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms. J Clin Oncol 2007;25(18 Suppl.): Abstract 14117.
   Google Scholar
• Chu X-J, DePinto W, Bartkovitz D, et al. Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J Med Chem 2006;49:6549–6560.
   PubMed Web of Science ®Google Scholar
• DePinto W, Chu X-J, Yin X, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006;5:2644–2658.
   PubMed Web of Science ®Google Scholar
• Diab S, Eckhardt S, Tan A, et al. A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs). J Clin Oncol 2007;25(Suppl.): Abstract 3528.
   Google Scholar
• Veselý J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994;224:771–786.
   PubMedGoogle Scholar
• De Azevedo WF, Leclerc S, Meijer L, et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human Cdk2 complexed with roscovitine. Eur J Biochem 1997; 243:518–526.
   PubMedGoogle Scholar
• Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases Cdc2, Cdk2 and Cdk5. Eur J Biochem 1997;243: 527–536.
   PubMedGoogle Scholar
• McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463–468.
   PubMed Web of Science ®Google Scholar
• Mgbonyebi OP, Russo J, Russo IH. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 1999;59:1903–1910.
   PubMed Web of Science ®Google Scholar
• Edamatsu H, Gau CL, Nemoto T, et al. CDK inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 2000;19:3059–3068.
   PubMed Web of Science ®Google Scholar
• Hahntow IN, Schneller F, Oelsner M, et al. Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004;18:747–755.
   PubMed Web of Science ®Google Scholar
• Alvi AJ, Austen B, Weston VJ, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005;105:4484–4491.
   PubMed Web of Science ®Google Scholar
• Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29–37.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Laurence V, et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 2010;46:3243–3250.
   PubMed Web of Science ®Google Scholar
• Misra RN, Xiao H, Kim KS, et al. N-(cycloalkylamino) acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004;47:1719–1728.
   PubMed Web of Science ®Google Scholar
• Chen R, Wierda WG, Chubb S, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009;113:4637–4645.
   PubMed Web of Science ®Google Scholar
• Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic Bcl-2 family members. Cancer Cell 2006;9:351–365.
   PubMed Web of Science ®Google Scholar
• Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008;8:121–132.
   PubMed Web of Science ®Google Scholar
• Del Gaizo Moore V, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires Bcl2 to sequester prodeath Bim, explaining sensitivity to Bcl2 antagonist ABT-737. J Clin Invest 2007;117:112–121.
   PubMed Web of Science ®Google Scholar
• Tong W-G, Chen R, Plunkett W, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010;28:3015–3022.
   PubMed Web of Science ®Google Scholar
• Burrows F, Goh K, Novotny-Diermayr V, et al. TG02: a novel, multi-kinase inhibitor with potent activity against solid tumors. J Clin Oncol 2010;28(Suppl.): Abstract e13549.
   Google Scholar
• Goh KC, Novotny-Diermayr V, Hart S, et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia 2012;26:236–243.
   PubMed Web of Science ®Google Scholar
• Pallis M, Abdul-Aziz A, Burrows F, et al. The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells. Br J Haematol 2012;159:191–203.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Khoury HJ, Shammo JM, et al. Phase I dose escalation study of TG02 in patients with advanced hematologic malignancies. J Clin Oncol 2012;30(Suppl.): Abstract 6577.
   Google Scholar
• Gojo I, Walker A, Cooper M, et al. Phase II study of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in patients with advanced acute leukemias. Blood 2010;116(Suppl. 1): Abstract 3287.
   Web of Science ®Google Scholar
• Yang X, Zhao X, Phelps MA, et al. A novel liposomal formulation of flavopiridol. Int J Pharm 2009;365:170–174.
   PubMed Web of Science ®Google Scholar